Gilead’s Trodelvy Redefines Breast Cancer Therapy with 38% Risk Reduction in Aggressive TNBC
Gilead Sciences’ antibody–drug conjugate (ADC) Trodelvy has demonstrated a 38 percent reduction in disease progression risk in patients with triple-negative breast cancer (TNBC), one of the most aggressive and treatment-resistant forms of the disease. The findings, presented at a major European oncology meeting, mark one of the most significant therapeutic advances for this subtype in…









